AbCellera Biologics Inc. (ABCL) Free cash flow
- Free cash flow · 12 months (USD): Value $-119.67M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -180.85%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-119.67M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-94.94M − $24.73M ≈ $-119.67M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -180.85% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-119.67M ÷ $66.17M × 100 ≈ -180.85% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-94.94M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.58× | Operating cash flow / net income. Period ending 2026-06-30. $-94.94M ÷ $-164.66M ≈ 0.58× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -94.94M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 24.73M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -119.67M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 66.17M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -164.66M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-119.67M | (m) | $-94.94M | $24.73M | (m) | $66.17M | (m) | $-164.66M | (m) | (m) | -180.85% | 0.58× |
| 2026-03-31 | $-189.23M | (m) | $-153.26M | $35.97M | (m) | $79.21M | (m) | $-143.96M | (m) | (m) | -238.90% | 1.06× |
| 2025-12-31 | $-174.07M | (m) | $-131.29M | $42.77M | (m) | $75.13M | (m) | $-146.41M | (m) | (m) | -231.69% | 0.90× |
| 2025-09-30 | $-153.11M | (m) | $-104.55M | $48.56M | (m) | $35.33M | (m) | $-171.68M | (m) | (m) | -433.44% | 0.61× |
| 2025-06-30 | $-138.99M | (m) | $-80.84M | $58.15M | (m) | $32.88M | (m) | $-165.66M | (m) | (m) | -422.76% | 0.49× |
| 2025-03-31 | $-143.29M | (m) | $-78.40M | $64.89M | (m) | $23.11M | (m) | $-167.87M | (m) | (m) | -619.94% | 0.47× |
| 2024-12-31 | $-186.95M | (m) | $-108.56M | $78.40M | (m) | $28.83M | (m) | $-162.86M | (m) | (m) | -648.40% | 0.67× |
| 2024-09-30 | $-197.36M | (m) | $-120.17M | $77.20M | (m) | $32.96M | (m) | $-175.80M | (m) | (m) | -598.76% | 0.68× |
| 2024-06-30 | $-170.40M | (m) | $-91.39M | $79.01M | (m) | $33.05M | (m) | $-153.30M | (m) | (m) | -515.53% | 0.60× |
| 2024-03-31 | $-127.63M | (m) | $-41.52M | $86.10M | (m) | $35.79M | (m) | $-146.90M | (m) | (m) | -356.62% | 0.28× |
| 2023-12-31 | $-120.82M | (m) | $-43.88M | $76.95M | (m) | $38.02M | (m) | $-146.40M | (m) | (m) | -317.75% | 0.30× |
| 2023-09-30 | $-68.20M | (m) | $6.65M | $74.85M | (m) | $50.39M | (m) | $-129.14M | (m) | (m) | -135.34% | -0.05× |
| 2023-06-30 | $-187.06M | (m) | $-120.03M | $67.03M | (m) | $145.18M | (m) | $-73.91M | (m) | (m) | -128.85% | 1.62× |
| 2023-03-31 | $61.93M | (m) | $133.08M | $71.15M | (m) | $181.03M | (m) | $-50.16M | (m) | (m) | 34.21% | -2.65× |
| 2022-12-31 | $206.70M | (m) | $277.36M | $70.66M | (m) | $485.42M | (m) | $158.52M | (m) | (m) | 42.58% | 1.75× |
| 2022-09-30 | $161.98M | (m) | $229.74M | $67.76M | (m) | $603.21M | (m) | $248.36M | (m) | (m) | 26.85% | 0.93× |
| 2022-06-30 | $286.77M | (m) | $350.59M | $63.82M | (m) | $507.32M | (m) | $200.35M | (m) | (m) | 56.53% | 1.75× |
| 2022-03-31 | $165.96M | (m) | $235.26M | $69.30M | (m) | $489.04M | (m) | $204.82M | (m) | (m) | 33.93% | 1.15× |
| 2021-12-31 | $186.13M | (m) | $244.58M | $58.45M | (m) | $375.20M | (m) | $153.46M | (m) | (m) | 49.61% | 1.59× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $13.02M | (m) | $22.69M | $9.67M | (m) | $233.16M | (m) | $118.92M | (m) | (m) | 5.58% | 0.19× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-1.30M | (m) | $2.69M | $4.00M | (m) | $11.61M | (m) | $-2.21M | (m) | (m) | -11.22% | -1.22× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |